Cargando…
Smoldering myocarditis following immune checkpoint blockade
BACKGROUND: Severe myocarditis associated with electrical conduction abnormalities and occasionally heart failure has been well documented following treatment with immune checkpoint blockade with an estimated incidence of less than 1%. However, the incidence, early detection, and management of less...
Autores principales: | Norwood, Timothy G., Westbrook, Brian C., Johnson, Douglas B., Litovsky, Silvio H., Terry, Nina L., McKee, Svetlana B., Gertler, Alan S., Moslehi, Javid J., Conry, Robert M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697345/ https://www.ncbi.nlm.nih.gov/pubmed/29157297 http://dx.doi.org/10.1186/s40425-017-0296-4 |
Ejemplares similares
-
Evolution of Immune Checkpoint Blockade–Induced Myocarditis Over 2 Years
por: Norwood, Timothy G., et al.
Publicado: (2020) -
Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients
por: Westbrook, Brian C., et al.
Publicado: (2019) -
Talimogene laherparepvec: First in class oncolytic virotherapy
por: Conry, Robert M., et al.
Publicado: (2018) -
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
por: Moslehi, Javid, et al.
Publicado: (2022) -
Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)